+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Respiratory Drugs Market Research Reports

From
Epithelial Sodium Channel (ENaC) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Epithelial Sodium Channel (ENaC) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
ARDS - Pipeline Insight, 2025 - Product Thumbnail Image

ARDS - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Ventilator Associated Pneumonia (VAP) - Pipeline Insight, 2025 - Product Thumbnail Image

Ventilator Associated Pneumonia (VAP) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Acute Lung Injury - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Lung Injury - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha- Antitrypsin Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha- Antitrypsin Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Nasal Polyposis - Pipeline Insight, 2025 - Product Thumbnail Image

Nasal Polyposis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Tuberculosis - Pipeline Insight, 2025 - Product Thumbnail Image

Tuberculosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Nosocomial Pneumonia - Pipeline Insight, 2025 - Product Thumbnail Image

Nosocomial Pneumonia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cystic Fibrosis - Pipeline Insight, 2025 - Product Thumbnail Image

Cystic Fibrosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 100 Pages
  • Global
From
Pertussis- Pipeline Insight, 2025 - Product Thumbnail Image

Pertussis- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Chronic Obstructive Lung Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Obstructive Lung Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2025 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Asthma - Pipeline Insight, 2025 - Product Thumbnail Image

Asthma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Pipeline Insight, 2025 - Product Thumbnail Image

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Bronchial Dysplasia - Pipeline Insight, 2025 - Product Thumbnail Image

Bronchial Dysplasia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Community-Acquired Bacterial Pneumonia (CABP) - Pipeline Insight, 2025 - Product Thumbnail Image

Community-Acquired Bacterial Pneumonia (CABP) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Obstructive Sleep Apnea (OSA) - Pipeline Insight, 2025 - Product Thumbnail Image

Obstructive Sleep Apnea (OSA) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Loading Indicator

The Respiratory Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat respiratory diseases. These drugs are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Commonly prescribed respiratory drugs include bronchodilators, corticosteroids, and antibiotics. The Respiratory Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Novartis, and Boehringer Ingelheim. These companies are constantly researching and developing new drugs to treat respiratory diseases, as well as improving existing treatments. Show Less Read more